Global  

NIH trial: Gilead's drug works best in COVID patients on oxygen

Reuters Saturday, 23 May 2020 ()
The U.S. National Institutes of Health (NIH) on Friday said that data from its trial of Gilead Sciences Inc's remdesivir show that the drug offers the most benefit for COVID-19 patients who need extra oxygen but do not require mechanical ventilation.
0
shares
ShareTweetSavePostSend
 

Related videos from verified sources

US Hospitals Cut Back On Use Of Hydroxychloroquine [Video]

US Hospitals Cut Back On Use Of Hydroxychloroquine

President Donald Trump promoted hydroxychloroquine, a malaria drug, as a COVID-19 treatment. According to Reuters, several studies suggest the drug isn’t effective against COVID-19 and creates..

Credit: Wochit Entertainment     Duration: 00:32Published
SD company starts clinical trial for drug that could help prevent use of ventilators for COVID-19 patients [Video]

SD company starts clinical trial for drug that could help prevent use of ventilators for COVID-19 patients

SD company starts clinical trial for drug that could help prevent use of ventilators for COVID-19 patients

Credit: ABC 10 News | San Diego     Duration: 02:04Published

Related news from verified sources

CytoDyn co-ordinates with Mexican Institutes of Health on leronlimab trial for severe coronavirus patients

CytoDyn Inc (OTCQB:CYDY) has announced plans to work with the Mexican National Institutes of Health (NIH) on a trial of leronlimab for severe coronavirus...
Proactive Investors

NIH begins study of remdesivir with anti-inflammatory drug to treat COVID-19

The National Institutes of Health said on Friday it has started a clinical study to test a combination of Gilead Sciences Inc's antiviral drug remdesivir and...
Reuters

You Might Like


Tweets about this